KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Major Shareholder Venrock Healthcare Capital Par Acquires 73,649 Shares

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) major shareholder Venrock Healthcare Capital Par bought 73,649 shares of KalVista Pharmaceuticals stock in a transaction dated Friday, February 7th. The stock was acquired at an average price of $9.29 per share, with a total value of $684,199.21. Following the completion of the transaction, the insider now directly owns 5,086,445 shares of the company's stock, valued at approximately $47,253,074.05. The trade was a 1.47 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Large shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Wednesday, February 12th, Venrock Healthcare Capital Par bought 100,000 shares of KalVista Pharmaceuticals stock. The stock was acquired at an average price of $9.23 per share, with a total value of $923,000.00.
• On Monday, February 10th, Venrock Healthcare Capital Par bought 4,137 shares of KalVista Pharmaceuticals stock. The stock was acquired at an average price of $9.14 per share, with a total value of $37,812.18.
• On Monday, February 3rd, Venrock Healthcare Capital Par bought 14,562 shares of KalVista Pharmaceuticals stock. The stock was acquired at an average price of $9.22 per share, with a total value of $134,261.64.
• On Thursday, January 30th, Venrock Healthcare Capital Par bought 43,707 shares of KalVista Pharmaceuticals stock. The stock was acquired at an average price of $8.76 per share, with a total value of $382,873.32.

KalVista Pharmaceuticals Stock Up 2.4 %

KALV stock traded up $0.23 during mid-day trading on Friday, hitting $9.76. 198,408 shares of the company were exchanged, compared to its average volume of 304,565. The firm has a market capitalization of $482.34 million, a P/E ratio of -2.68 and a beta of 0.85. The business has a fifty day simple moving average of $8.75 and a 200-day simple moving average of $10.54. KalVista Pharmaceuticals, Inc. has a 12-month low of $7.30 and a 12-month high of $16.88.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last announced its earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.01. Research analysts predict that KalVista Pharmaceuticals, Inc. will post -3.56 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. SG Americas Securities LLC boosted its stake in shares of KalVista Pharmaceuticals by 10.0% in the fourth quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company's stock valued at $123,000 after purchasing an additional 1,319 shares during the period. HighVista Strategies LLC boosted its stake in shares of KalVista Pharmaceuticals by 4.5% in the third quarter. HighVista Strategies LLC now owns 33,305 shares of the specialty pharmaceutical company's stock valued at $386,000 after purchasing an additional 1,432 shares during the period. Legal & General Group Plc boosted its stake in shares of KalVista Pharmaceuticals by 22.5% in the fourth quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company's stock valued at $69,000 after purchasing an additional 1,494 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of KalVista Pharmaceuticals by 8.0% in the third quarter. JPMorgan Chase & Co. now owns 22,610 shares of the specialty pharmaceutical company's stock valued at $262,000 after purchasing an additional 1,670 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of KalVista Pharmaceuticals by 24.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company's stock valued at $87,000 after purchasing an additional 2,043 shares during the period.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on KALV shares. Cantor Fitzgerald restated an "overweight" rating on shares of KalVista Pharmaceuticals in a research report on Monday, December 9th. Citizens Jmp upgraded shares of KalVista Pharmaceuticals to a "strong-buy" rating in a research report on Friday, January 31st. Bank of America started coverage on shares of KalVista Pharmaceuticals in a research report on Wednesday, December 18th. They set a "buy" rating and a $22.00 price objective for the company. TD Cowen started coverage on shares of KalVista Pharmaceuticals in a research report on Tuesday, January 7th. They set a "buy" rating and a $30.00 price objective for the company. Finally, Needham & Company LLC restated a "buy" rating and set a $28.00 price objective on shares of KalVista Pharmaceuticals in a research report on Thursday, December 5th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $23.80.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).